1. Children and COVID-19: State Data Report. A joint report from the American Academy of Pediatrics and the Children’s Hospital Association Summary of publicly reported data from 49 states, NYC, DC, PR, and GU. Version:3/10/2022 2022.
2. Hammond J , Leister-Tebbe H , Gardner A . Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022.
3. US Food and Drug Administration (FDA) . Fact sheet for healthcare providers: emergency use authorization for Paxlovid (nirmatrelvir and ritonavir), 2021. Available: https://www.fda.gov/media/155050/download [Accessed 22 Dec 2021].
4. In the age of Omicron variant: Paxlovid raises new hopes of COVID‐19 recovery
5. ClinicalTrials.gov . EPIC-HR: study of oral PF-07321332/Ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. ClinicalTrials.gov identifier: NCT04960202 . Available: https://clinicaltrials.gov/ct2/show/NCT04960202 [Accessed 27 Dec 2021].